Welcome to UroGen
UroGen has a steadfast commitment to elevating options for people living with urological cancers. Through breakthrough technology, we are removing barriers to treatment and shaping a future filled with new possibilities in transformative therapies.
Innovation that champions patients
With a portfolio fueled by ongoing innovation, we have redefined options for patients. Our transformative therapies have changed the landscape of what was previously possible.
Possibilities brought to life
UroGen's FDA-approved treatments leverage our innovative RTGel technology to provide patients with more options.
Our innovative science
Our pipeline is focused on innovative treatments designed to help uro-oncology patients.
Explore UroGen news
Jan 5, 2026
Permanent J Code for ZUSDURI™ Now in Effect, Expanding Patient Access to Innovative Bladder Cancer Therapy
about Permanent J Code for ZUSDURI™ Now in Effect, Expanding Patient Access to Innovative Bladder Cancer Therapy
Dec 5, 2025
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
about UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov 25, 2025
UroGen Pharma to Present at the Piper Sandler 37th Annual Healthcare Conference
about UroGen Pharma to Present at the Piper Sandler 37th Annual Healthcare Conference
Nov 6, 2025
UroGen Reports Third Quarter 2025 Financial Results as ZUSDURI™ Launch Gains Momentum
about UroGen Reports Third Quarter 2025 Financial Results as ZUSDURI™ Launch Gains Momentum
Nov 6, 2025
UroGen Reports 77.8% Three-Month Complete Response Rate from Phase 3 UTOPIA Trial of UGN-103 and Receives FDA Agreement on NDA Submission Strategy in Recurrent LG-IR-NMIBC Based on UTOPIA Trial
about UroGen Reports 77.8% Three-Month Complete Response Rate from Phase 3 UTOPIA Trial of UGN-103 and Receives FDA Agreement on NDA Submission Strategy in Recurrent LG-IR-NMIBC Based on UTOPIA Trial
Nov 4, 2025
UroGen Pharma to Present at Guggenheim Securities Healthcare Innovation Conference
about UroGen Pharma to Present at Guggenheim Securities Healthcare Innovation Conference
Oct 30, 2025
UroGen Pharma to Report Third Quarter 2025 Financial Results on Thursday, November 6th, 2025
about UroGen Pharma to Report Third Quarter 2025 Financial Results on Thursday, November 6th, 2025
Oct 27, 2025
Centers for Medicare and Medicaid Services Assigns Permanent J Code for ZUSDURI™ Effective January 1, 2026
about Centers for Medicare and Medicaid Services Assigns Permanent J Code for ZUSDURI™ Effective January 1, 2026
Oct 2, 2025
ZUSDURI™ Clinical Review Published in Reviews in Urology™ Highlights Durable Efficacy and Manageable Safety Profile in Recurrent Low-Grade, Intermediate-Risk Non–Muscle Invasive Bladder Cancer
about ZUSDURI™ Clinical Review Published in Reviews in Urology™ Highlights Durable Efficacy and Manageable Safety Profile in Recurrent Low-Grade, Intermediate-Risk Non–Muscle Invasive Bladder Cancer
Sep 8, 2025
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
about UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)